Latest News and Press Releases

LOUISVILLE, CO--(Marketwired - May 27, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM) today announced top line results from the GS-4774 Phase 2 study in patients with chronic hepatitis B on long term...

LOUISVILLE, CO--(Marketwired - May 14, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM) today announced its first quarter 2015 financial results and corporate highlights."We are pleased with the progress...

LOUISVILLE, CO--(Marketwired - April 22, 2015) - GlobeImmune, Inc. today announced that a randomized Phase 2 clinical trial designed to investigate the safety and efficacy of GI-6301 in combination...

LOUISVILLE, CO--(Marketwired - March 17, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM) today provided an update on the Company's business and clinical programs, and announced financial results for the full...

LOUISVILLE, CO--(Marketwired - March 02, 2015) - GlobeImmune, Inc., (NASDAQ: GBIM) today announced that Timothy C. Rodell, M.D., Chief Executive Officer, will present at the 27th Annual ROTH...

LOUISVILLE, CO--(Marketwired - February 03, 2015) - GlobeImmune, Inc., (NASDAQ: GBIM) today announced that Timothy C. Rodell, M.D., Chief Executive Officer, will present at the 17th Annual BIO CEO...

LOUISVILLE, CO--(Marketwired - November 12, 2014) - GlobeImmune, Inc. (NASDAQ: GBIM), today announced its third quarter 2014 financial results and corporate highlights."Following the completion of...

BERLIN, GERMANY--(Marketwired - October 17, 2014) - GlobeImmune, Inc., today announced that updated results from eleven chordoma patients in the GI-6301 Phase 1 trial were presented at the 2014 CTOS...

LOUISVILLE, CO--(Marketwired - September 30, 2014) - GlobeImmune, Inc. (NASDAQ: GBIM) today announced that Timothy C. Rodell, M.D., Chief Executive Officer, will present at the 13th Annual BioInvestor...

LOUISVILLE, CO--(Marketwired - September 18, 2014) - GlobeImmune, Inc. (NASDAQ: GBIM) today announced that Timothy C. Rodell, M.D., Chief Executive Officer, will present at the 21st Annual BioCentury...